Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Trial of ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma

Next Previous
Trial Profile

A Phase II Trial of ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Jan 2019

At a glance

  • Drugs Docetaxel (Primary) ; Gemcitabine (Primary) ; Pegargiminase (Primary)
  • Indications Soft tissue sarcoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 30 May 2018 According to a Polaris Pharmaceuticals media release, the first patient has been dosed in this phase 2 study.
    • 22 May 2018 Planned End Date changed from 9 May 2026 to 9 Feb 2025.
    • 22 May 2018 Planned primary completion date changed from 9 May 2026 to 9 May 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top